Overview

Prazosin for Agitation in Alzheimer's Disease

Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
Phase:
Phase 2
Details
Lead Sponsor:
Alzheimer's Disease Cooperative Study (ADCS)
Collaborators:
Alzheimer's Association
National Institute on Aging (NIA)
VA Puget Sound Health Care System
Treatments:
Prazosin